Burn Patients Clinical Trial
Official title:
Soluble Factors in the Serum of Severely Burned Patients
The present study investigates the levels of certain soluble factors in the blood of patients with severe burn injury. Serum levels of different soluble factors will be correlated with the clinical outcome, presence of sepsis, the area of burn, and other clinical parameters in order to make a statement regarding their use as biomarkers in the prediction and monitoring of burn patients.
Burn patients still represent a critical patient collective with a high mortality rate
although treatment technologies have improved over the years. One problem healthcare
professionals face is the fact that reliable biomarker which predict the clinical outcome,
the onset of sepsis, and monitor the severity of disease in burn patients are still missing.
These biomarkers would allow an early adoption of treatment modalities to improve the
outcome and prevent life-threatening complications.
Blood samples from severely burned patients will be collected over a period of five days and
different cytokines (for example the macrophage migration inhibitory factor protein family)
will be measured in the serum. Clinical data of the patients (sepsis, total body surface
area of burns, abbreviated burn severity index, sepsis-related organ failure assessment,
etc.) will be documented and correlated to the levels of soluble factors.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT02872272 -
Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population
|
Phase 4 | |
| Completed |
NCT01497990 -
Pharmacokinetics Ertapenem Burns
|
Phase 4 | |
| Completed |
NCT03742648 -
The Effectiveness of Deep Breathing Exercises and Incentive Spirometry in Second Degree Inhalation Burn Patients
|
N/A |